Quest Diagnostics exec acquires 37 shares via DRIP
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition. On April 20, 2026, he acquired 37 shares of Quest Diagnostics common stock at $194.696 per share through a dividend reinvestment plan under Rule 16a-6. Following this transaction, he directly holds 11,901 common shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Small Acquisition | Common Stock | 37 | $194.696 | $7K |
Footnotes (2)
- F1. Represents an award of restricted share units.
- F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Key Terms
dividend reinvestment plan financial
Rule 16a-6 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Quest Diagnostics (DGX) report for Mark E. Delaney?
What does the transaction code "L" mean in the Quest Diagnostics (DGX) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.